Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We sought to develop a matrix assisted laser desorption ionization-time of flight (MALDITOF)- based, ovarian cancer (OVC), low-mass-ion discriminant equation (LOME) and to evaluate a possible supportive role for triple-TOF mass analysis in identifying metabolic biomarkers. Materials and Methods A total of 114 serum samples from patients with OVC and benign ovarian tumors were subjected to MALDI-TOF analysis and a total of 137 serum samples from healthy female individuals and patients with OVC, colorectal cancer, hepatobiliary cancer, and pancreatic cancer were subjected to triple-TOF analysis. An OVC LOME was constructed by reference to the peak intensity ratios of discriminatory low-mass ion (LMI) pairs. Triple-TOF analysis was used to select and identify metabolic biomarkers for OVC screening. Results Three OVC LOMEs were finally constructed using discriminatory LMI pairs (137.1690 and 84.4119 m/z; 496.5022 and 709.7642 m/z; and 524.5614 and 709.7642 m/z); all afforded accuracies of > 90%. The LMIs at 496.5022 m/z and 524.5614 m/z were those of lysophosphatidylcholine (LPC) 16:0 and LPC 18:0. Triple-TOF analysis selected seven discriminative LMIs; each LMI had a specificity > 90%. Of the seven LMIs, four with a 137.0455 m/z ion at retention times of 2.04-3.14 minutes were upregulated in sera from OVC patients; the ion was identified as that derived from hypoxanthine. Conclusion MALDI-TOF–based OVC LOMEs combined with triple-TOF–based OVC metabolic biomarkers allow reliable OVC screening; the techniques are mutually complementary both quantitatively and qualitatively.
Abstract
Purpose We sought to develop a matrix assisted laser desorption ionization-time of flight (MALDITOF)- based, ovarian cancer (OVC), low-mass-ion discriminant equation (LOME) and to evaluate a possible supportive role for triple-TOF mass analysis in identifying metabolic biomarkers. Materials and Methods A total of 114 serum samples from patients with OVC and benign ovarian tumors were subjected to MALDI-TOF analysis and a total of 137 serum samples from healthy female individuals and patients with OVC, colorectal cancer, hepatobiliary cancer, and pancreatic cancer were subjected to triple-TOF analysis. An OVC LOME was constructed by reference to the peak intensity ratios of discriminatory low-mass ion (LMI) pairs. Triple-TOF analysis was used to select and identify metabolic biomarkers for OVC screening. Results Three OVC LOMEs were finally constructed using discriminatory LMI pairs (137.1690 and 84.4119 m/z; 496.5022 and 709.7642 m/z; and 524.5614 and 709.7642 m/z); all afforded accuracies of > 90%. The LMIs at 496.5022 m/z and 524.5614 m/z were those of lysophosphatidylcholine (LPC) 16:0 and LPC 18:0. Triple-TOF analysis selected seven discriminative LMIs; each LMI had a specificity > 90%. Of the seven LMIs, four with a 137.0455 m/z ion at retention times of 2.04-3.14 minutes were upregulated in sera from OVC patients; the ion was identified as that derived from hypoxanthine. Conclusion MALDI-TOF–based OVC LOMEs combined with triple-TOF–based OVC metabolic biomarkers allow reliable OVC screening; the techniques are mutually complementary both quantitatively and qualitatively.
참고문헌 (12)
- 김윤환, "Recent advances in the biomarkers for epithelial ovarian cancer", Journal of Gynecologic Oncology, 22(4), pp.219~221 (2011), 대한부인종양학회
- Menon U, "Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)", Lancet Oncol, 10, pp.327~340 (2009)[DOI]
- Jacobs IJ, "Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial", Lancet, 387, pp.945~956 (2016)[DOI]
- Buys SS, "Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial", JAMA, 305, pp.2295~2303 (2011)[DOI]
- Lee JH, "Lowmass-ion discriminant equation (LOME) for ovarian cancer screening", BioData Min, 9, pp.32~ (2016)[DOI]
- Lee JH, "Low-mass-ion discriminant equation: a new concept for colorectal cancer screening", Int J Cancer, 134, pp.1844~1853 (2014)[DOI]
- 김건, "Identification of Hypoxanthine and Phosphoenolpyruvic Acid as Serum Markers of Chemoradiotherapy Response in Locally Advanced Rectal Cancer", Cancer Research and Treatment, 47(1), pp.78~89 (2015), 대한암학회[DOI]
- Yoo BC, "Identification of hypoxanthine as a urine marker for non-Hodgkin lymphoma by low-mass-ion profiling", BMC Cancer, 10, pp.55~ (2010)[DOI]
- Lorenzi M, "The determination of urinary oxypurines as markers of gastrointestinal tumors", Tumori, 73, pp.289~294 (1987)[DOI]
- Jung J, "Noninvasive diagnosis and evaluation of curative surgery for gastric cancer by using NMR-based metabolomic profiling", Ann Surg Oncol, 21(Suppl 4), pp.S736~S742 (2014)[DOI]
- Kyriakides M, "Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy", Oncotarget, 7, pp.7216~7226 (2016)
- Chan TC, "Role of hypoxanthine and thymidine in determining methotrexate plus dipyridamole cytotoxicity", Eur J Cancer, 26, pp.907~911 (1990)[DOI]